The first shipments of dolutegravir to two upper-middle-income countries, Azerbaijan and Belarus, under a licensing deal agreed by the Medicines Patent Pool have been announced by the MPP.
Last November, the MPP and ViiV Healthcare signed a new voluntary licensing agreement to enable greater access for dolutegravir-based regimens in certain upper-middle-income countries
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?